ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

RPRX Company Profile and Key Details

NASDAQ : RPRX

Royalty Pharma plc

$32.17

-0.43-1.32%

Open: 2:45 PM

68.03

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Royalty Pharma plc (RPRX) stock declined over -1.32%, trading at $32.17 on NASDAQ, down from the previous close of $32.60. The stock opened at $32.09, fluctuating between $32.02 and $32.69 in the recent session.

Stock Snapshot

32.6

Prev. Close

32.09

Open

13.94B

Market Cap

433.32M

Number of Shares

32.02

Day Low

32.69

Day High

16.84

P/E Ratio

77.14%

Free Float in %

1.91

EPS (TTM)

14.61

Book Value

1.96

Cash Flow per Share

911.18K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 17, 2025	32.09	32.67	32.09	32.60	2.54M
Apr 16, 2025	32.56	32.61	32.02	32.19	3.02M
Apr 15, 2025	32.34	32.51	32.04	32.45	2.88M
Apr 14, 2025	32.22	32.32	31.77	32.29	2.73M
Apr 11, 2025	31.44	32.01	30.96	31.95	5.9M
Apr 10, 2025	31.97	31.97	30.31	31.21	6.59M
Apr 09, 2025	30.15	32.31	30.04	32.27	7.3M
Apr 08, 2025	31.03	31.60	30.53	30.85	6.12M
Apr 07, 2025	29.80	31.14	29.66	31.05	5.63M
Apr 04, 2025	31.30	31.70	30.45	31.11	7.26M
Apr 03, 2025	31.05	31.85	30.99	31.79	5.75M
Apr 02, 2025	31.06	31.36	30.82	31.28	4.64M
Apr 01, 2025	31.25	31.51	30.99	31.17	4.7M
Mar 31, 2025	30.89	31.31	30.64	31.13	7.61M
Mar 28, 2025	31.74	31.80	31.00	31.37	4.08M
Mar 27, 2025	31.87	32.25	31.24	31.65	7.56M
Mar 26, 2025	33.49	34.00	31.38	31.56	10.88M
Mar 25, 2025	33.85	34.14	33.50	33.76	5.12M
Mar 24, 2025	33.60	33.99	33.60	33.75	2.35M
Mar 21, 2025	33.30	33.84	33.25	33.70	7.07M

Contact Details

New York, NY 10022

United States

Website: https://www.royaltypharma.comContact: 212 883 0200

About Company

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Frequently Asked Questions

What is the current Royalty Pharma plc (RPRX) stock price?

Royalty Pharma plc (NASDAQ: RPRX) stock price is $32.17 in the last trading session. During the trading session, RPRX stock reached the peak price of $32.69 while $32.02 was the lowest point it dropped to. The percentage change in RPRX stock occurred in the recent session was -1.32% while the dollar amount for the price change in RPRX stock was -$0.43.

RPRX's industry and sector of operation?

The NASDAQ listed RPRX is part of Biotechnology industry that operates in the broader Healthcare sector. Royalty Pharma plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RPRX?

Mr. George Grofik C.F.A., C.P.A.
Senior Vice President and Head of Investor Relations & Communications
Ms. Alessandra Sassun
Senior Vice President & Head of Human Capital
Mr. Arthur R. McGivern J.D.
Executive Vice President of Investments & Gen. Counsel
Mr. Ashwin Pai M.D.
Executive Vice President of Investments
Ms. Kristin Stafford
Senior Vice President & Chief Accounting Officer
Dr. James Folmar Reddoch Ph.D.
Executive Vice President of Investments & Chief Scientific Officer
Mr. George Grofik C.F.A., CPA
Senior Vice President and Head of Investor Relations & Communications
Mr. Pablo Gerardo Legorreta
Founder, Chairman & Chief Executive Officer
Mr. Terrance P. Coyne
Executive Vice President & Chief Financial Officer
Mr. George Wingate Lloyd
Executive Vice President of Investments & Chief Legal Officer
Mr. Christopher Hite
Vice Chairman & Executive Vice President
Dr. Marshall Urist M.D., Ph.D.
Executive Vice President and Head of Research & Investments

How RPRX did perform over past 52-week?

RPRX's closing price is 35.55% higher than its 52-week low of $24.05 where as its distance from 52-week high of $34.20 is -4.68%.

How many employees does RPRX have?

Number of RPRX employees currently stands at 75.

Link for RPRX official website?

Official Website of RPRX is: https://www.royaltypharma.com

How do I contact RPRX?

RPRX could be contacted at phone 212 883 0200 and can also be accessed through its website. RPRX operates from 110 East 59th Street, New York, NY 10022, United States.

How many shares of RPRX are traded daily?

RPRX stock volume for the day was 911.18K shares. The average number of RPRX shares traded daily for last 3 months was 5.06M.

What is the market cap of RPRX currently?

The market value of RPRX currently stands at $13.94B with its latest stock price at $32.17 and 433.32M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

News

Investing Crypto Market Business US Stocks

Useful Links

Screener Market Data Insider Transactions Upgrades & Downgrades 52 Week Highs & Lows Unusual Volume Dividend Calendar Earnings Calendar

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	75
Beta	0.49
Sales or Revenue	$2.35B
5Y Sales Change%	0.038%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology